Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2000

View Archived Issues

Genetic cause of lymphedema discovered by U. of Pittsburgh researchers

Company Profile: Genteric

Randomized study of tafenoquine as malaria chemoprophylaxis

Vical licenses naked DNA technology to Aventis

Vasopressin V1a receptor antagonist aids in prevention of dysmenorrhea

Atrix receives Canadian marketing approval for Atridox

Angiostatin combined with radiation therapy enters phase I trials

Alizyme successfully concludes phase Ia trial of ATL-962 for treatment of obesity

Final results of phase II study of Synsorb Cd reported by Synsorb Biotech

Novel vaccine appears to clear amyloid plaques from the brain and prevent their formation

New benzazepine selectively targets tumor cells and induces G2/M arrest and apoptosis

Chemoprotective effects of KF-41399 demonstrated in nimustine-treated mice

Novel approach to AD discussed at World Alzheimer Congress: intranasal ADNP-derived peptide

FDA advisory committee recommends approval of LeuTech for imaging infection

ST-6: a new cardioprotective agent hypothesized to block sodium overload during ischemia

Shortened Taxol regimen approved by FDA for advanced ovarian cancer

Tumor antigen-specific chimeric proteins from Idec promote antitumor immune response

Hydrazine-based inhibitors of TNF-alpha release described by Roche

Patent recently issued to BASF covering new PARP inhibitors and their use

Immunosuppressive humanized antibodies designed by LG Chemical

Novel cystatin protein expressed in testis and potential uses thereof described by ZymoGenetics

Shionogi presents new cephem antibiotics

Japanese laboratories discover naturally produced chymase inhibitors

Orally active human elastase inhibitors developed under collaborative Cortech-Ono effort

Maxim licenses caspase-activating anticancer compounds to BioChem Pharma

KS Biomedix seeks approval to begin clinical trials of anticancer antibody

Axokine phase II obesity trial completes enrollment

CINP news: AC-5216 appears superior to diazepam in the treatment of anxiety and depression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...